85 related articles for article (PubMed ID: 33171591)
1. Unlocking the potential of flavonoid-based co-crystal and co-amorphous systems.
Rode K; Maji I; Mahajan S; Singh PK
Drug Discov Today; 2024 Jun; 29(7):104050. PubMed ID: 38830502
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
3. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined therapy of valsartan and rosuvastatin on patients with atrial fibrillation.
Hu WM; Shi ZH; Wu DY; Ye SY; Xiang YJ; Liu C; Chen JC; Zeng CL
J Biol Regul Homeost Agents; 2020; 34(6):2215-2220. PubMed ID: 33185084
[No Abstract] [Full Text] [Related]
5. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
[No Abstract] [Full Text] [Related]
6. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Camacho A; Iyer SR; Maisel AS; Felker GM; Butler J; Piña IL; Ibrahim NE; Abbas C; Burnett JC; Solomon SD; Januzzi JL
JACC Heart Fail; 2021 Feb; 9(2):127-136. PubMed ID: 33189632
[TBL] [Abstract][Full Text] [Related]
7. Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.
Khayyat-Kholghi M; Oparil S; Davis BR; Tereshchenko LG
JACC Heart Fail; 2021 Feb; 9(2):100-111. PubMed ID: 33189627
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old.
Weersink RA; Alvarez-Alvarez I; Medina-Cáliz I; Sanabria-Cabrera J; Robles-Díaz M; Ortega-Alonso A; García-Cortés M; Bonilla E; Niu H; Soriano G; Jimenez-Perez M; Hallal H; Blanco S; Kaplowitz N; Lucena MI; Andrade RJ
Clin Pharmacol Ther; 2021 Apr; 109(4):1147-1158. PubMed ID: 33179256
[TBL] [Abstract][Full Text] [Related]
9. Surface Modifiers on Composite Particles for Direct Compaction.
Chen FC; Liu WJ; Zhu WF; Yang LY; Zhang JW; Feng Y; Ming LS; Li Z
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297653
[TBL] [Abstract][Full Text] [Related]
10. Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.
Liu J; Grohganz H; Löbmann K; Rades T; Hempel NJ
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33804159
[TBL] [Abstract][Full Text] [Related]
11. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
[TBL] [Abstract][Full Text] [Related]
12. Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs.
Davis M; Walker G
J Control Release; 2018 Jan; 269():110-127. PubMed ID: 29117503
[TBL] [Abstract][Full Text] [Related]
13. Spray drying formulation of amorphous solid dispersions.
Singh A; Van den Mooter G
Adv Drug Deliv Rev; 2016 May; 100():27-50. PubMed ID: 26705850
[TBL] [Abstract][Full Text] [Related]
14. Combining Co-Amorphous-Based Spray Drying with Inert Carriers to Achieve Improved Bioavailability and Excellent Downstream Manufacturability.
Zhang Y; Gao Y; Du X; Guan R; He Z; Liu H
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33171591
[TBL] [Abstract][Full Text] [Related]
15. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
16. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.
Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S
Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
